Ocutrx Vision Technologies, LLC, a California-based manufacturer of augmented reality (AR) glasses, has announced that the company’s founder and CEO recently detailed its breakthrough eye-tracking technology from their flagship Oculenz ARwear glasses to an audience of healthcare CEO’s, visionaries and analysts at the 3rd Annual Medical Devices Innovation Conference in Boston, Massachusetts.
Freeman served as a thought leader for the AR medical device space at the conference, which featured a wide array of the brightest minds and medical device innovators who design, develop, manufacture and commercialize life-saving products. Freeman shared the stage with a distinguished healthcare panel including Johnson & Johnson/DePuy Synthes Companies’ Director of Enabling Technologies, Emir Osmanagic, and Google’s Senior Program Manager, Heidi Dohse. The Associate Director of Device and Digital Health at Merck & Co., Inc., George Cusatis, MS, RAC introduced Freeman to the audience.
The annual Medical Devices Conference was developed as an opportunity to bring together key healthcare decision makers and medical device developers to discuss what’s happening in the industry today and prepare for what’s coming next. Attendees receive unparalleled insight into the latest cutting-edge technologies and approaches disrupting the medical devices industry.
“It was an honor to share the stage with some of the brightest minds in the medical device technology space at such an important and prestigious event,” said Freeman. “The ideas expressed—and technology shared—at this conference will likely shape the future of our healthcare and medical devices. The feedback we’ve received here for our patented technology and freshly redesigned Oculenz AR wear glasses is both humbling and motivating to continue to push the boundaries of AR/XR for medical devices to help patients with low vision conditions to lead healthy, enriched lives.”
At the event, Freeman walked the audience through the groundbreaking eye-tracking technology Ocutrx is currently pioneering as well as provided a sneak-peek at the incredible results of very successful early clinical trials for the company’s ARwear glasses. Freeman also discussed the growth of the AR medical device market for technology aimed at assisting patients with low vision in their everyday lives (as well as professionals in executing specialized tasks), the encouraging and overwhelmingly positive reception their technology is receiving in the medical community, amongst patients, media and industry analysts and much more.
